Mark Christianson Sells 10,000 Shares of NeuroOne Medical Technologies (NASDAQ:NMTC) Stock

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Director Mark Christianson sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $3.18, for a total value of $31,800.00. Following the sale, the director owned 20,692 shares in the company, valued at $65,800.56. The trade was a 32.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

NeuroOne Medical Technologies Price Performance

NASDAQ:NMTC opened at $3.00 on Friday. The business’s 50 day moving average is $3.80 and its two-hundred day moving average is $4.38. NeuroOne Medical Technologies Corporation has a 52 week low of $2.89 and a 52 week high of $6.96. The company has a market cap of $26.10 million, a PE ratio of -3.53 and a beta of 0.54.

NeuroOne Medical Technologies (NASDAQ:NMTC) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). The firm had revenue of $1.86 million during the quarter, compared to the consensus estimate of $2.58 million. NeuroOne Medical Technologies had a negative net margin of 68.35% and a negative return on equity of 99.43%. As a group, sell-side analysts expect that NeuroOne Medical Technologies Corporation will post -0.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

NMTC has been the topic of a number of research reports. Zacks Research cut shares of NeuroOne Medical Technologies from a “strong-buy” rating to a “hold” rating in a report on Friday, March 13th. Weiss Ratings lowered shares of NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, May 11th. Finally, LADENBURG THALM/SH SH boosted their price objective on shares of NeuroOne Medical Technologies from $1.60 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, May 13th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $11.67.

Institutional Investors Weigh In On NeuroOne Medical Technologies

Several large investors have recently added to or reduced their stakes in the stock. Legato Capital Management LLC bought a new stake in NeuroOne Medical Technologies in the fourth quarter valued at $34,000. Squarepoint Ops LLC acquired a new stake in shares of NeuroOne Medical Technologies in the 4th quarter worth about $36,000. Susquehanna International Group LLP acquired a new stake in shares of NeuroOne Medical Technologies in the 3rd quarter worth about $47,000. XTX Topco Ltd bought a new stake in NeuroOne Medical Technologies in the 2nd quarter valued at about $51,000. Finally, Goldman Sachs Group Inc. bought a new stake in NeuroOne Medical Technologies in the 1st quarter valued at about $84,000. 16.07% of the stock is owned by institutional investors and hedge funds.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.